Biren Amin
Stock Analyst at Piper Sandler
(1.05)
# 3,511
Out of 4,837 analysts
61
Total ratings
32.73%
Success rate
-18.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $2.70 | +529.63% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.11 | +530.63% | 3 | May 14, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $110 → $70 | $40.05 | +74.78% | 7 | May 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $46 → $63 | $32.84 | +91.84% | 2 | Apr 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $28.14 | +81.27% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $12.88 | +195.03% | 1 | Mar 31, 2025 | |
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.32 | +120.89% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $35.56 | +113.72% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $2.06 | +482.52% | 1 | Feb 19, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $74 → $71 | $27.25 | +160.55% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $4 | $4.13 | -3.15% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.41 | +372.33% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $7.92 | +165.15% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $65.54 | +75.47% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $17.42 | +83.70% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.66 | -18.03% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.31 | +105.34% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.21 | +5,685.12% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.38 | +13,243.80% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.25 | +966.67% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.89 | +1,076.47% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $4.00 | +12,400.00% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.12 | +173.44% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $604.62 | +14.29% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.04 | +390.20% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.97 | - | 4 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $20.81 | +385.46% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $120.53 | -42.75% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $435.32 | -64.39% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.45 | +9,279.31% | 4 | Mar 6, 2017 |
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $2.70
Upside: +529.63%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.11
Upside: +530.63%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $110 → $70
Current: $40.05
Upside: +74.78%
BridgeBio Pharma
Apr 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $32.84
Upside: +91.84%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $28.14
Upside: +81.27%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $12.88
Upside: +195.03%
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.32
Upside: +120.89%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $35.56
Upside: +113.72%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $2.06
Upside: +482.52%
Viking Therapeutics
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $27.25
Upside: +160.55%
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.13
Upside: -3.15%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $7.41
Upside: +372.33%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $7.92
Upside: +165.15%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $65.54
Upside: +75.47%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $17.42
Upside: +83.70%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.66
Upside: -18.03%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $7.31
Upside: +105.34%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.21
Upside: +5,685.12%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.38
Upside: +13,243.80%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $2.25
Upside: +966.67%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.89
Upside: +1,076.47%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $4.00
Upside: +12,400.00%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $5.12
Upside: +173.44%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $604.62
Upside: +14.29%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.04
Upside: +390.20%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.97
Upside: -
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $20.81
Upside: +385.46%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $120.53
Upside: -42.75%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $435.32
Upside: -64.39%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.45
Upside: +9,279.31%